David Henry Michael Steffin MD Stem Cell Transplant/Immunotherapy
Assistant professor performing clinical research in Phase 1 CAR T cell trials for pediatric solid tumors, with a clinical focus in Hematopoietic Stem Cell Transplantation
Join to View Full Profile
6701 Fannin St Ste 1510Clinical Care Center Texas Childrens HospitalHouston, TX 77030
Phone+1 832-822-4242
Dr. Steffin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicineFellowship, Pediatric Stem Cell Transplant, 2018 - 2019- Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2015 - 2018
Maimonides Medical Center/Infants and Children's Hospital of BrooklynResidency, Pediatrics, 2012 - 2015
Technion-Israel Inst of Technology Faculty of MedicineClass of 2012
Certifications & Licensure
TX State Medical License 2015 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Start of enrollment: 2021 Dec 08
Publications & Presentations
PubMed
- Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors.Aaron B Ross, Kriti Puri, Thomas L Johnson, Lilliam D Correa, Tami D John
Pediatric Blood & Cancer. 2025-04-01 - 3 citationsLong-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma.Che-Hsing Li, Sandhya Sharma, Andras A Heczey, Mae L Woods, David H M Steffin
Nature Medicine. 2025-02-17 - 7 citationsInterleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney
Nature. 2025-01-01
Press Mentions
From Bench to Bedside and Back: CAR T Cells Armed with IL-15 Show Promise in Treating Solid CancersJanuary 28th, 2025- Study Shows Long-Term Safety of Genetically Modified Immune Effector CellsMarch 31st, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
